

22 April 2026
Medclair AB (publ)

Communiqué from the Annual General Meeting of Medclair AB

The Annual General Meeting of Medclair was held in Stockholm on April 22, 2026. A summary of the resolutions follows below.

Resolution on the adoption of accounts and appropriation of profit

The meeting adopted the income statement and balance sheet as well as the consolidated income statement and consolidated balance sheet and resolved, in accordance with the proposal of the Board of Directors and the CEO, that the year's results be appropriated according to the Board's proposal in the annual report.

Discharge from liability

The meeting granted the members of the Board of Directors and the CEO discharge from liability for the 2025 financial year.

Election and remuneration of the Board and auditor

Fredrik Crafoord, Mark Baljeu, Jens Johansson, and Martin Roos were elected to the Board. Fredrik Crafoord was elected as Chairman. Allians Revision & Redovisning was elected as auditor, with Sofia Gunnarsson as the auditor in charge. The meeting resolved that Board fees shall be paid in the amount of SEK 220,000 to the Chairman of the Board and SEK 140,000 to each of the Board members. The auditor shall be remunerated according to approved invoices.

Resolution on authorization for the Board to resolve on issues

The meeting resolved to authorize the Board, during the period until the next Annual General Meeting, on one or more occasions and with or without deviation from the shareholders' preferential rights, to resolve on the new issue of shares, convertibles, and/or warrants. Payment may be made in cash, in kind, by set-off, or otherwise be associated with conditions.

The company's share capital and the number of shares may, with the support of the authorization, be increased by a total maximum amount and number, respectively, that fall within the limits of the articles of association. Deviation from the shareholders' preferential rights shall be permitted in order to strengthen the company's financial position if necessary and to enable the acquisition of companies or businesses. In the event of deviation from the shareholders' preferential rights and in the case of payment in kind or by set-off, the issue price shall correspond to the market value of the share with—where applicable—a market-based issue discount.

22 April 2026
Medclair AB (publ)

For further information, please contact:

Jonas Lundh, Medclair AB (publ), Phone: +46 76 193 90 90, Email: jonas.lundh@medclair.com

About Us

Medclair is a Swedish cleantech company and a leader in safe and sustainable nitrous oxide management. With operations in twenty countries, Medclair provides innovative solutions that significantly reduce the climate impact of nitrous oxide while improving workplace safety.

The company is listed on NGM Nordic SME. For more information, please visit www.medclair.com.

This information is information that Medclair is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-04-22 18:05 CEST.